Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial-Reference-Cited by-同舟云学术

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Published:2018-01 Issue:10118 Volume:391 Page:319-328
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ridker Paul M,MacFadyen Jean G,Everett Brendan M,Libby Peter,Thuren Tom,Glynn Robert J,Ridker Paul M,MacFadyen Jean G,Everett Brendan M,Libby Peter,Thuren Tom,Glynn Robert J,Kastelein John,Koenig Wolfgang,Genest Jacques,Lorenzatti Alberto,Varigos John,Siostrzonek Peter,Sinnaeve Peter,Fonseca Francisco,Nicolau Jose,Gotcheva Nina,Yong Huo,Urina-Triana Miguel,Milicic Davor,Cifkova Renata,Vettus Riina,Anker Stephan D,Manolis Athanasios J,Wyss Fernando,Forster Tamas,Sigurdsson Axel,Pais Prem,Fucili Alessandro,Ogawa Hisao,Shimokawa Hiroaki,Veze Irina,Petrauskiene Birute,Salvador Leon,Cornel Jan Hein,Klemsdal Tor Ole,Medina Felix,Budaj Andrzej,Vida-Simiti Luminita,Kobalava Zhanna,Otasevic Petar,Pella Daniel,Lainscak Mitja,Seung Ki-Bae,Commerford Patrick,Dellborg Mikael,Donath Marc,Hwang Juey-Jen,Kultursay Hakan,Flather Marcus,Ballantyne Christie,Bilazarian Seth,Chang William,East Cara,Forgosh Les,Harris Barry,Ligueros Monica

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Inflammation, atherosclerosis, and coronary artery disease;Hansson;N Engl J Med,2005

2. Inflammation in atherosclerosis: from pathophysiology to practice;Libby;J Am Coll Cardiol,2009

3. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N Engl J Med,2017

4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS);Ridker;Am Heart J,2011

5. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial;Ridker;Lancet,2017

Cited by 648 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of vulnerable patient phenotypes and acute coronary syndrome mechanisms;International Journal of Cardiology;2024-11

2. Elastin-specific MR probe for visualization and evaluation of an interleukin-1β targeted therapy for atherosclerosis;Scientific Reports;2024-09-04

3. Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotype;Atherosclerosis;2024-09

4. Advances in the Management of Cardiovascular Disease in the Setting of Human Immunodeficiency Virus;Infectious Disease Clinics of North America;2024-09

5. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease;European Heart Journal;2024-08-30